

Date: May 15, 2024

To,

BSE Limited,
Department of Corporate Services,
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai- 400001
BSE Scrip Code: 533014

Dear Sir/Madam,

Sub: Outcome of Board meeting

In continuation of our letter dated 30th April, 2024, we wish to inform you that the Board of Directors of the Company at its meeting held on today i.e. on 15th May, 2024 has inter alia;

1. Approved the Audited Financial Results (both Standalone & Consolidated) of the Company for the Quarter and year ended 31st March, 2024.
2. Recommended Equity Dividend at 6% (60 paise per share) for the Financial Year 2023-24, subject to approval of shareholders at the 20th Annual General Meeting (AGM) of the Company.
3. The report of Auditors is with unmodified opinion with respect to the Audited Financial Results (both Standalone & Consolidated) of the Company for the Quarter and year ended 31st March, 2024.

Pursuant to Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, copies of the aforesaid Audited Financial Results together with the Auditor's report are enclosed herewith.

Declaration of unmodified opinion and large corporate disclosure are provided in Annexure A and Annexure B respectively.

The meeting of the Board of Directors commenced at 11:30 a.m. (IST) & concluded at 02:30 p.m. (IST).

The above intimation be kindly be taken into record.

Thanking You,

**Yours sincerely,
For Sicagen India Limited**


**(Ankita Jain)
Company Secretary**



Encl: as above

Sicagen India Ltd.

Registered & Corporate Office:

4th Floor, SPIC House, 88, Mount Road, Guindy, Chennai 600 032 INDIA

Tel: +91 44 4075 4075 | Fax: +91 44 4075 4099 | info@sicagen.com

CIN No.: L74900TN2004PLC053467 | www.sicagen.com